WT1 peptide-based cancer vaccine for long-term maintenance of anti-tumor immunity

Not Applicable

Recruiting

• Conditions: solid tumor, malignant lymphoma, acute leukemia

• Registration Number: JPRN-UMIN000015997
• Lead Sponsor: Osaka University Graduate Shool of Medicine, Functional Diagnostic Science

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-12-20
• Study Completion: 2018-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

Not provided

Exclusion Criteria

1. having severe infectious disease 2. having developed adverse effects (grade >=4) in the prior WT1 peptide vaccine trial 3. having severe complications 4. having severe mental disorders

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
DTH to WT1 peptide Frequency of WT1 specific CTLs

Secondary Outcome Measures

Name	Time	Method
Safety 1 Numbers and frequencies of adverse effects defined in NCI-CTCAE v4.0 2 Frequencies of hematological- and non-hematological adverse effects which result in suspension or withdrawal of WT1 peptide vaccine Anti-tumor effects Anti-tumor effects are evaluated at 3-6 months intervals by the method described elsewhere.